Profile data is unavailable for this security.
About the company
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. It also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.
- Revenue in GBP (TTM)2.04bn
- Net income in GBP336.02m
- Incorporated2005
- Employees8.70k
- LocationHikma Pharmaceuticals PLC1 New Burlington PlaceLONDON W1S 2HRUnited KingdomGBR
- Phone+44 207 399 2760
- Fax+44 207 399 2761
- Websitehttps://www.hikma.com/
Mergers & acquisitions
| Acquired company | HIK:LSE since announced | Transaction value |
|---|---|---|
| Teligent Inc-Sterile Injectable Assets | -18.46% | 36.45m |
| CUSTOpharm Inc | -29.74% | 425.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genus plc | 569.80m | 35.70m | 1.76bn | 3.10k | 49.23 | 3.45 | 24.93 | 3.08 | 0.5428 | 0.5428 | 8.66 | 7.74 | 0.6557 | -- | 5.19 | 184,043.90 | 4.07 | 3.30 | 4.79 | 3.85 | -- | -- | 6.21 | 5.21 | 1.46 | -- | 0.272 | 66.72 | 4.15 | 8.14 | 33.99 | -0.8249 | 12.69 | 8.38 |
| Indivior PLC | 652.89m | 132.49m | 2.21bn | 802.00 | 18.13 | 11.98 | 14.72 | 3.38 | 0.1732 | 0.1732 | 0.8547 | 0.2623 | 0.4906 | 1.45 | 4.54 | 814,073.20 | 9.96 | 6.98 | 17.02 | 14.26 | 83.86 | 86.32 | 20.29 | 12.43 | 1.61 | 8.17 | 0.5486 | 0.00 | 22.26 | -5.65 | 238.51 | 42.41 | -0.5781 | -- |
| Abcam Plc | 315.40m | 3.90m | 2.55bn | 1.75k | 654.93 | 3.89 | 55.79 | 8.10 | 0.017 | 0.017 | 1.38 | 2.87 | 0.3487 | 1.79 | 6.68 | 180,228.60 | 0.4312 | -- | 0.4979 | -- | 71.21 | -- | 1.24 | -- | 0.8189 | 56.20 | 0.2593 | -- | -- | -- | -- | -- | -- | -- |
| Dechra Pharmaceuticals plc | 640.60m | 72.90m | 3.77bn | 1.95k | 51.87 | 5.89 | 23.16 | 5.88 | 0.6697 | 0.6697 | 5.89 | 5.90 | 0.5375 | 1.90 | 7.42 | 329,357.30 | 6.12 | 3.37 | 6.87 | 3.79 | 56.88 | 56.47 | 11.38 | 6.85 | 1.75 | 13.57 | 0.3314 | 97.78 | 18.04 | 19.69 | 63.72 | 34.37 | 78.18 | 17.02 |
| Hikma Pharmaceuticals Plc | 2.04bn | 336.02m | 3.78bn | 8.70k | 11.76 | 2.01 | 8.06 | 1.85 | 1.44 | 1.44 | 8.75 | 8.46 | 0.6002 | 1.72 | 3.70 | 234,135.00 | 9.87 | 3.80 | 13.05 | 5.21 | 50.96 | 50.90 | 16.45 | 6.61 | 1.38 | 10.35 | 0.2554 | 71.43 | 9.06 | 5.54 | -2.32 | 22.12 | 3.80 | 11.07 |
| Croda International Plc | 1.89bn | 320.80m | 9.42bn | 6.14k | 29.43 | 5.38 | 21.60 | 4.99 | 2.29 | 2.29 | 13.52 | 12.57 | 0.5978 | 2.55 | 6.02 | 308,003.30 | 10.21 | 11.17 | 11.75 | 13.16 | 49.69 | 43.71 | 17.08 | 16.39 | 0.98 | 23.60 | 0.3464 | 61.78 | 35.91 | 8.73 | 59.13 | 10.28 | 8.53 | 5.70 |
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 23 Feb 2022 | 11.20m | 4.95% |
| JPMorgan International Bank Ltd.as of 02 Apr 2022 | 10.75m | 4.75% |
| BlackRock Advisors (UK) Ltd.as of 04 Mar 2022 | 10.13m | 4.48% |
| Capital Research & Management Co. (World Investors)as of 23 Feb 2022 | 7.64m | 3.38% |
| Norges Bank Investment Managementas of 02 Apr 2022 | 4.24m | 1.87% |
| The Vanguard Group, Inc.as of 02 Apr 2022 | 3.60m | 1.59% |
| Northern Trust Global Investments Ltd. (Securities Lending)as of 02 Apr 2022 | 3.33m | 1.47% |
| Franklin Templeton Institutional LLCas of 31 Mar 2022 | 3.13m | 1.38% |
| Capital Research & Management Co. (Global Investors)as of 02 Apr 2022 | 2.95m | 1.31% |
| Templeton Investment Counsel LLCas of 02 Apr 2022 | 1.92m | 0.85% |
